All questions
Clinical trials: Taltz (ixekizumab) in plaque psoriasis 11 questions · 3 sources
Questions that apply to every indication of Taltz are on Taltz (ixekizumab), all indications .
Study results How effective is Taltz for plaque psoriasis at Week 12 (UNCOVER trials)? Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
“Three multicenter, randomized, double-blind, placebo-controlled trials, Trials 1, 2, and 3 (NCT 01474512, NCT 01597245, NCT 01646177), enrolled a total of 3866 subjects 18 years of age and older with plaque psoriasis who had a minimum body surface area involvement of 10%, a static Physician Global Assessment (sPGA) score of ≥3 in the overall assessment (plaque thickness/induration, erythema, and scaling) of psoriasis on a severity scale of 0 to 5, a Psoriasis Area and Severity Index (PASI) score ≥12, and who were candidates for phototherapy or systemic therapy.” (opens the source at this quote in a new tab) Copy Flag
“In an NRI analysis of UNCOVER-1 (Taltz n=433; placebo n=431), UNCOVER-2 (Taltz n=351; placebo n=168), and UNCOVER-3 (Taltz n=385; placebo n=193), at week 12, 89%, 90% and 87% of patients receiving Taltz, respectively, achieved PASI 75 vs 4%, 2%, and 7% for placebo, respectively; 71%, 71% and 68% of patients receiving Taltz, respectively, achieved PASI 90 vs 1%, 1%, and 3% for placebo, respectively; 35%, 40% and 38% of patients receiving Taltz, respectively, achieved PASI 100 vs 0%, 1%, and 0% for placebo, respectively.” (opens the source at this quote in a new tab) Copy Flag
“In UNCOVER-1, -2, and -3, 82%, 83%, and 81% of Taltz patients, respectively, achieved sPGA 0,1 at 12 weeks vs 3%, 2%, and 7% for placebo.” (opens the source at this quote in a new tab) Copy Flag
Note: The Prescribing Information calls these trials Trials 1, 2, and 3; the Taltz HCP site calls them UNCOVER-1, -2, and -3. Table 3 columns are TALTZ 80 mg Q2W and placebo for Trial 1, Trial 2, and Trial 3, in that order. Trials 2 and 3 also had an etanercept arm, which this answer does not include.
How fast does Taltz improve plaque psoriasis (UNCOVER-3)? Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
“In an observed analysis of UNCOVER-3 (Taltz n=385; placebo n=193), at weeks 2, 4, 8, and 12 (the induction period), patients receiving Taltz achieved mean percentage improvement in PASI from baseline of 56%, 74%, 86%, and 92%, respectively, vs 11%, 13%, 15%, and 14% for placebo, respectively. Additionally, at weeks 36, 48, 60, 108, 156, 204, and 264 (the open-label extension period), patients receiving Taltz achieved 95%, 95%, 96%, 95%, 96%, 97% and 97% of mean percentage improvement in PASI from baseline, respectively.” (opens the source at this quote in a new tab) Copy Flag
Itch relief Does Taltz relieve psoriasis itch at Week 12? Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Note: The row is from Table 3 of the Prescribing Information (Week 12, non-responder imputation). Its columns are TALTZ 80 mg Q2W and placebo for Trial 1, Trial 2, and Trial 3, in that order, as n (%).
Maintenance of response Does Taltz maintain clear or almost clear skin through Week 60 (UNCOVER-1 and -2)? Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
What happens when Taltz is stopped after psoriasis clears? Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Long-term results Does Taltz keep working for psoriasis through 5 years (UNCOVER-3)? Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
“In an observed analysis of UNCOVER-3 (Taltz N=385), at week 12, 72% of patients achieved PASI 90, and 40% of patients achieved PASI 100. Additionally, at weeks 60, 108, 156, 204, and 264, 84%, 81%, 87%, 88%, and 90% of patients, respectively, achieved PASI 90; and 64%, 58%, 65%, 67%, and 66% of patients, respectively, achieved PASI 100.” (opens the source at this quote in a new tab) Copy Flag
“In an mNRI analysis of UNCOVER-3, at week 12, 70% of patients achieved PASI 90, and 39% of patients achieved PASI 100. Additionally, at weeks 60, 108, 156, 204, and 264, 78%, 71%, 69%, 66%, and 67% of patients, respectively, achieved PASI 90; and 59%, 50%, 49%, 48%, and 46% of patients, respectively, achieved PASI 100.” (opens the source at this quote in a new tab) Copy Flag
Subgroup results Does Taltz work for scalp psoriasis? Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
“In the post hoc mNRI analysis of UNCOVER-3 study, among patients with scalp psoriasis (Taltz n=349; placebo n=176), patients receiving Taltz at weeks 12 (the induction period), 60, 108, 156, 204, and 264 (the open-label extension period), 78%, 81%, 78%, 74%, 64%, and 69% of patients, respectively, achieved PSSI=0; at week 12, 10% of patients on placebo achieved PSSI=0.” (opens the source at this quote in a new tab) Copy Flag
On the page, select: Scalp data (PSSI 0)
Does Taltz work for nail psoriasis? Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
“In the post hoc mNRI analysis of UNCOVER-3 study, among patients with nail psoriasis (Taltz n=229; placebo n=116), patients receiving Taltz at weeks 12 (the induction period), 60, 108, 156, 204, and 264 (the open-label extension period), 18%, 65%, 65%, 70%, 60%, and 64% of patients, respectively, achieved NAPSI=0; at week 12, 4% of patients on placebo achieved NAPSI=0.” (opens the source at this quote in a new tab) Copy Flag
Does Taltz work for palmoplantar (hand and foot) psoriasis? Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
“In the post hoc mNRI analysis of UNCOVER-3 study, among patients with palmoplantar psoriasis (Taltz n=96; placebo n=54), patients receiving Taltz at weeks 12 (the induction period), 60, 108, 156, 204, and 264 (the open-label extension period), 65%, 78%, 79%, 72%, 78%, and 75% of patients, respectively, achieved PPASI 100; at week 12, 30% of patients on placebo achieved PPASI 100.” (opens the source at this quote in a new tab) Copy Flag
How effective is Taltz for genital psoriasis? Applies to Adults with plaque psoriasis involving the genital area
“In the NRI analysis of IXORA-Q study, among patients with genital psoriasis (Taltz n=75; placebo n=74), patients receiving Taltz at week 12 (the induction period), 24, and 52 (the open-label extension period), 56%, 61% and 60% of patients achieved sPGA-G 0 response; at week 12, 5% of patients on placebo achieved sPGA-G 0 response.
NRI of intent-to-treat population through week 52.
In NRI analysis, 73% of Taltz patients achieved sPGA-G 0,1 at week 12 compared to 8% of placebo (primary endpoint).
The open-label phase of the study beginning after week 12 has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).
Data were from a pre-specified, exploratory endpoint and not controlled for type-I error.” (opens the source at this quote in a new tab) Copy Flag
On the page, select: Genital data (sPGA-G 0)
Note: The first two passages are from the Prescribing Information, which reports Trial 4; the third is from the Taltz HCP site, which reports IXORA-Q. Table 4 columns are TALTZ 80 mg Q2W and placebo.
Pediatric efficacy How effective is Taltz in children with plaque psoriasis (IXORA-Peds)? Applies to Moderate-to-severe plaque psoriasis in pediatric patients 6 to less than 18 years of age
“Table 5: Efficacy Results in Pediatric Subjects with Plaque Psoriasis in IXORA-Peds, NRIa
a Abbreviations: N = Number of subjects in the intent-to-treat population; NRI = Non-Responder Imputation.
b At Week 0, subjects received 160 mg, 80 mg, or 40 mg of TALTZ, followed by 80 mg, 40 mg, or 20 mg every 4 weeks, depending on weight category, for 12 weeks.
c Co-primary endpoints.
d Itch NRS (≥4 improvement) in subjects with baseline Itch NRS ≥4. The number of ITT subjects with baseline Itch NRS Score ≥4 are as follows: TALTZ, n = 83; PBO, n = 40.
TALTZb
(N=115)
n (%) Placebo
(N=56)
n (%)
Week 12
sPGA “0” (clear) or “1” (minimal)c 93 (81%) 6 (11%)
sPGA “0” (clear) 60 (52%) 1 (2%)
PASI 75c 102 (89%) 14 (25%)
PASI 90 90 (78%) 3 (5%)
PASI 100 57 (50%) 1 (2%)
Itch NRS (≥4 point improvement)d 59 (71%) 8 (20%)
Week 4
sPGA “0” (clear) or “1” (minimal) 55 (48%) 4 (7%)
PASI 75 62 (54%) 5 (9%)” (opens the source at this quote in a new tab) Copy Flag
Note: Table 5 columns are TALTZ and placebo, as n (%).